LOGIN  |  REGISTER
Cue Biopharma

ICU Medical to Participate in Upcoming Investor Conferences

August 21, 2024 | Last Trade: US$129.90 1.97 -1.49

SAN CLEMENTE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September:

Wells Fargo 2024 Healthcare Conference on September 4, 2024

Vivek Jain, Chief Executive Officer, will attend one-on-one meetings at the Wells Fargo 2024 Healthcare Conference in Boston on Wednesday, September 4, 2024.

Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024

Vivek Jain, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Friday, September 6, 2024. The discussion will begin at 4:00 a.m. PT (7:00 a.m. ET) and will be webcast live on the Event Calendar section of the Company’s Investor Relations website at https://ir.icumed.com. A replay of the webcast will be archived on the website for future viewing. Company management will also participate in one-on-one meetings at the conference.

About ICU Medical

ICU Medical (Nasdaq:ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com

CONTACT:
ICU Medical
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page